OBJECTIVE: To assess if the reduction in HIV-1 RNA in CD4 T cells is correlated with the persistence of immune activation following early antiretroviral therapy (ART). DESIGN: Clinical trial (NCT01285050). METHODS: Next-generation sequencing was used to study total RNA from activated CD4 T cells (CD38 and human leukocyte antigen - antigen D related (HLA-DR) expressing) collected from 19 treatment-naïve HIV-1/hepatitis C virus-infected patients before and early after ART initiation (≥12 weeks after plasma HIV-1 RNA <50 copies/ml). To validate comparisons, pre and post-ART measures were adjusted for input RNA and overall read number. RESULTS: As expected, ART use was associated with a median [interquartile range (IQR)] 4.3% (2.2-8.3) reduction in the proportion of activated CD4 T cells (P = 0.0008). Whereas in those activated CD4 T cells no consistent differences in overall gene expression were detected, interferon-stimulated gene expression declined (P < 2 × 10). Pre-ART, sorted activated CD4 T cells contained a median (IQR) of 959 (252-1614) HIV-1 reads/10 reads compared with 72 (55-152) HIV-1 reads/10 reads after at least 12 weeks of suppressive ART (P = 8 × 10). The decrease in HIV-1 reads in activated CD4 T cells was associated with the change in plasma HIV-1 RNA levels (r = 0.77, P = 2 × 10) and the change in the proportion of activated CD4 T cells (r = 0.70, P = 0.0016). CONCLUSION: Months of ART led to a marked decrease in cell-associated HIV-1 RNA and interferon-stimulated genes expression in activated CD4 T cells that were strongly associated with the reduction in the proportion of activated CD4 T cells.
OBJECTIVE: To assess if the reduction in HIV-1 RNA in CD4 T cells is correlated with the persistence of immune activation following early antiretroviral therapy (ART). DESIGN: Clinical trial (NCT01285050). METHODS: Next-generation sequencing was used to study total RNA from activated CD4 T cells (CD38 and human leukocyte antigen - antigen D related (HLA-DR) expressing) collected from 19 treatment-naïve HIV-1/hepatitis C virus-infectedpatients before and early after ART initiation (≥12 weeks after plasma HIV-1 RNA <50 copies/ml). To validate comparisons, pre and post-ART measures were adjusted for input RNA and overall read number. RESULTS: As expected, ART use was associated with a median [interquartile range (IQR)] 4.3% (2.2-8.3) reduction in the proportion of activated CD4 T cells (P = 0.0008). Whereas in those activated CD4 T cells no consistent differences in overall gene expression were detected, interferon-stimulated gene expression declined (P < 2 × 10). Pre-ART, sorted activated CD4 T cells contained a median (IQR) of 959 (252-1614) HIV-1 reads/10 reads compared with 72 (55-152) HIV-1 reads/10 reads after at least 12 weeks of suppressive ART (P = 8 × 10). The decrease in HIV-1 reads in activated CD4 T cells was associated with the change in plasma HIV-1 RNA levels (r = 0.77, P = 2 × 10) and the change in the proportion of activated CD4 T cells (r = 0.70, P = 0.0016). CONCLUSION: Months of ART led to a marked decrease in cell-associated HIV-1 RNA and interferon-stimulated genes expression in activated CD4 T cells that were strongly associated with the reduction in the proportion of activated CD4 T cells.
Authors: Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano Journal: Nat Med Date: 2003-05-18 Impact factor: 53.440
Authors: Ning Leng; John A Dawson; James A Thomson; Victor Ruotti; Anna I Rissman; Bart M G Smits; Jill D Haag; Michael N Gould; Ron M Stewart; Christina Kendziorski Journal: Bioinformatics Date: 2013-02-21 Impact factor: 6.937
Authors: T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci Journal: Proc Natl Acad Sci U S A Date: 1997-11-25 Impact factor: 11.205
Authors: Michael M Lederman; Nicholas T Funderburg; Rafick P Sekaly; Nichole R Klatt; Peter W Hunt Journal: Adv Immunol Date: 2013 Impact factor: 3.543
Authors: Vivek Jain; Wendy Hartogensis; Peter Bacchetti; Peter W Hunt; Hiroyu Hatano; Elizabeth Sinclair; Lorrie Epling; Tzong-Hae Lee; Michael P Busch; Joseph M McCune; Christopher D Pilcher; Frederick M Hecht; Steven G Deeks Journal: J Infect Dis Date: 2013-07-12 Impact factor: 5.226
Authors: Ashwin Balagopal; David M Asmuth; Wei-Teng Yang; Thomas B Campbell; Nikhil Gupte; Laura Smeaton; Cecilia Kanyama; Beatriz Grinsztejn; Breno Santos; Khuanchai Supparatpinyo; Sharlaa Badal-Faesen; Javier R Lama; Umesh G Lalloo; Fatima Zulu; Jyoti S Pawar; Cynthia Riviere; Nagalingeswaran Kumarasamy; James Hakim; Xiao-Dong Li; Richard B Pollard; Richard D Semba; David L Thomas; Robert C Bollinger; Amita Gupta Journal: J Acquir Immune Defic Syndr Date: 2015-10-01 Impact factor: 3.731
Authors: Nicole E Skinner; Candelaria Vergara; Ramy El-Diwany; Harry Paul; Alyza Skaist; Sarah J Wheelan; David L Thomas; Stuart C Ray; Ashwin Balagopal; Justin R Bailey Journal: Viral Immunol Date: 2021-10-21 Impact factor: 2.175
Authors: Jeffrey R Quinn; Ashish Goyal; Ruy M Ribeiro; Guido Massaccesi; Justin R Bailey; David L Thomas; Ashwin Balagopal Journal: AIDS Date: 2022-03-01 Impact factor: 4.632
Authors: Sean Matthew McCauley; Kyusik Kim; Anetta Nowosielska; Ann Dauphin; Leonid Yurkovetskiy; William Edward Diehl; Jeremy Luban Journal: Nat Commun Date: 2018-12-13 Impact factor: 14.919